Wexford Capital’s Kite Pharma, Inc. KITE Stock Holding History

Wexford Capital’s Portfolio KITE Stock Details KITE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-3,700	Closed	-$384K	–	212
2017 Q2	$384K	Buy	+3,700	New	+$302K	0.03%	120

Other funds holding KITE

Cowen Inc New York $1.39B AUM 60.14% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

WCM

Wildcat Capital Management New York $229M AUM 132.65% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

TCSAM

Tyrus Capital S.A.M. Monaco $10.5M AUM 4.88% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Wexford Capital's KITE Position: Q3 2017 in Review

Wexford Capital sold out of Kite Pharma, Inc. (KITE) in Q3 2017, closing a stake of 3,700 shares — an estimated $384K sold.

Wexford Capital first reported a position in KITE in Q2 2017 and held it in 1 quarter. The position peaked at $384K in Q2 2017. 244 funds tracked by Wall St. Rank hold KITE as of Q3 2017.

Wexford Capital reported no remaining Kite Pharma, Inc. position as of Q3 2017 after selling out during the quarter.
Wexford Capital sold 3,700 Kite Pharma, Inc. shares in Q3 2017, an estimated $384K.
Wexford Capital first reported a position in Kite Pharma, Inc. in Q2 2017 and held it in 1 quarter.
Wexford Capital's Kite Pharma, Inc. position peaked at $384K in Q2 2017.
244 funds tracked by Wall St. Rank held Kite Pharma, Inc. as of Q3 2017.

Based on Wexford Capital's 13F filing for Q3 2017, filed 13 Nov 2017.